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Abstract
Introduction: Fractalkine is a chemokine implicated as a mediator in a variety of inflammatory conditions.
Knowledge of fractalkine release in patients presenting with infection to the Intensive Care Unit (ICU) is highly limited.
The primary objective of this study was to establish whether plasma fractalkine levels are elevated in sepsis and associate
with outcome. The secondary objective was to determine whether fractalkine can assist in the diagnosis of infection
upon ICU admission.
Methods: Fractalkine was measured in 1103 consecutive sepsis patients (including 271 patients with
community-acquired pneumonia (CAP)) upon ICU admission and at days 2 and 4 thereafter; in 73 ICU patients
treated for suspected CAP in whom this diagnosis was refuted in retrospect; and in 5 healthy humans
intravenously injected with endotoxin.
Results: Compared to healthy volunteers, sepsis patients had strongly elevated fractalkine levels. Fractalkine levels
increased with the number of organs failing, were higher in patients presenting with shock, but did not vary by site of
infection. Non-survivors had sustained elevated fractalkine levels when compared to survivors. Fractalkine was equally
elevated in CAP patients and patients treated for CAP but in whom the diagnosis was retrospectively refuted. Fractalkine
release induced by intravenous endotoxin followed highly similar kinetics as the endothelial cell marker E-selectin.
Conclusions: Plasma fractalkine is an endothelial cell derived biomarker that, while not specific for infection, correlates
with disease severity in sepsis patients admitted to the ICU.
Introduction
Sepsis is a life-threatening condition that represents a
great health burden [1] and the most frequent cause of
death in non-coronary intensive care units (ICUs) in the
developed world [2]. The annual incidence of severe
sepsis in the USA is estimated at 300 cases per 100,000
person-years population, which accounts for 10 % of all
ICU admissions [3]. The mortality of severe sepsis and
septic shock lies between 25 and 50 %, with the extent
and number of organs failing as the strongest predictors
of an adverse outcome [2]. The clinical syndrome of sepsis
is the consequence of a deregulated immune response to
infection that is injurious to the host’s tissues and organs.
The harmful host response during sepsis involves both
disproportionate proinflammatory and immune suppres-
sive anti-inflammatory components [1].
Fractalkine (CX3CL1) is a CX3C chemokine, which
was first described to be produced by endothelial cells
[4]. Subsequent research identified several additional
cellular sources of fractalkine, including epithelial cells,
neurons, microglial cells, osteoblasts, smooth muscle
cells, dendritic cells, lymphocytes and macrophages [5, 6].
Fractalkine has a membrane-bound form and a soluble
form [7]. The membrane-bound form functions as an
adhesion protein, whereas soluble fractalkine acts as a
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chemokine [6]. The receptor for fractalkine, CX3CR1, is
expressed by T cells, natural killer cell subsets, brain
microglia, dendritic cell subsets, blood monocytes, and
thrombocytes [5, 8, 9]. Fractalkine has been implicated as
a mediator in several inflammatory conditions, including
atherosclerosis, atopic dermatitis, airway hyper respon-
siveness, multiple sclerosis, and Crohn’s disease [10–12].
Recent studies have suggested that fractalkine plays a
role in the pathogenesis of sepsis. Mice with polymicro-
bial abdominal sepsis caused by cecal ligation and punc-
ture (CLP) have elevated fractalkine levels in their
peritoneal lavage fluid and serum [13–15]. CX3CR1-defi-
cient mice have enhanced mortality after CLP, suggesting
that fractalkine contributes to protective immunity
during sepsis [13]. Knowledge of fractalkine levels in a
setting of clinical sepsis is limited to a single study that
described elevated serum concentrations in 43 patients
with septic shock [16]. In the present study, we analyzed
sequential plasma fractalkine levels in 1,103 sepsis
patients during the first 4 days of ICU admission and
determined their association with the source of infec-
tion, organ failure and survival. In addition, we evaluated
the possible cellular source of fractalkine by studying
healthy humans injected with endotoxin. Finally, we de-
termined whether fractalkine levels can be discriminative
of infection upon ICU admission by performing analyses
in 344 patients presenting with suspected community-
acquired pneumonia (CAP).
Methods
Study design, patients and definitions
From January 2011 through July 2013 consecutive patients
presenting to the mixed ICUs of two tertiary teaching
hospitals (Academic Medical Center in Amsterdam and
University Medical Center Utrecht) were included. Data
and plasma samples were prospectively collected as part
of the molecular diagnosis and risk stratification of sepsis
(MARS) project, a large prospective observational study
(ClinicalTrials.gov identifier NCT01905033) [17–23].
Organ failure was defined as a score of 3 or greater on the
Sequential Organ Failure Assessment (SOFA) score,
except for cardiovascular failure for which a score of 1 or
more was used [24]. Shock was defined as the use of vaso-
pressors (noradrenaline) for hypotension in a dose of 0.1
mcg/kg/min during at least 50 % of the ICU day. The
plausibility of infection was scored post hoc based on all
available evidence and classified on a 4-point scale (none,
possible, probable or definite) according to Center for
Disease Control and Prevention [25] and International
Sepsis Forum consensus definitions [26], as described in
detail previously [17]. Readmissions and patients trans-
ferred from another ICU were excluded, except for patients
referred to one of the study centers on the day of admis-
sion. Daily (on admission and at 6 a.m. thereafter) left-over
EDTA plasma (obtained from blood drawn for patient
care) was stored within 4 hours at –80 °C. The Medical
Ethical Committees of both study centers gave approval
for an opt-out consent method (IRB no. 10-056C). The
Municipal Personal Records Database was consulted to
determine survival up to one year after ICU admission.
The primary objective of this study was to establish
whether plasma fractalkine levels are elevated in sepsis
and are associated with outcome. For this we analyzed all
patients with sepsis diagnosed within 24 hours of admis-
sion, defined as a ‘definite’ or ‘probable’ infection [17]
combined with at least one general, inflammatory, or
hemodynamic, organ dysfunction, or tissue perfusion
parameters derived from the 2001 International Sepsis
Definitions Conference [27]. The secondary objective was
to determine whether fractalkine can assist in the diagno-
sis of infection upon ICU admission. For this, we selected
all patients with CAP from this sepsis cohort and com-
pared these with all patients presenting with suspected
CAP, for which the clinical team started therapeutic anti-
biotics, but in retrospect were classified as having an
infection likelihood of ‘none’, as described previously [19].
Experimental human endotoxemia
Five healthy non-smoking male volunteers (mean age
21, range 19–22 years) were intravenously administered
4 ng/kg lipopolysaccharide (LPS) (from Escherichia coli
O113, CC-RE lot 3), kindly provided by Dr. Anthony
Suffredini (National Institutes of Health, Bethesda, MD,
USA). Blood was collected in EDTA tubes immediately
before injection, and 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0,
8.0, 12.0, and 20.0 hours thereafter. The study was ap-
proved by the Medical Ethics Commission of the AMC,
Amsterdam, The Netherlands, and written informed
consent was obtained from all subjects.
Assays
Fractalkine, soluble E-Selectin, interleukin (IL)-6, IL-8, IL-
10 and TNF-α levels were measured by cytometric bead
array (BD Biosciences, San Jose, CA, USA) using a FACS
Calibur flow cytometer (BD Biosciences). IL-6 levels in
plasma from subjects injected with LPS were determined
by Luminex multiplex assay using BioPlex 200 (BioRad,
Hercules, CA, USA). Normal biomarker values were
acquired from EDTA plasma from 27 age- and gender-
matched healthy volunteers, from whom written informed
consent was obtained.
Statistical analysis
Data are represented by box and whisker plots. Two-
group comparisons were performed with the Wilcoxon
rank-sum test; for multiple groups Kruskal-Wallis analysis
followed by Dunn’s test was used. The primary endpoint
for association with mortality was set at day 30 after ICU
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admission. Mixed-effects models were used to compare
survivors with non-survivors over time. The log-rank test
was performed to compare survival in quartiles of fractalk-
ine levels on ICU admission. Correlation was determined
using Spearman’s rho test. Multivariable logistic regression
was used to establish the independent prognostic value of
fractalkine after adjustment for age, Charlson comorbidity
index, body mass index, admission type and severity of
disease (Acute Physiology and Chronic Health Evaluation
(APACHE) IV or Sequential Organ Failure Assessment
(SOFA)). Variables in the model were checked for
collinearity by calculating the variance inflation factor.
The area under the receiver operating characteristics
(ROC) curve (AUC, or the C statistic) and 95 % confi-
dence intervals (CI), considering 2000 bootstrap repli-
cates, were determined to examine the performance of
fractalkine in predicting 30-day mortality. The optimal
threshold was determined using the Youden index for se-
lection of the highest sum of sensitivity and specificity. Dif-
ferences in the predictive power of fractalkine and soluble
E-selectin was studied by comparing the ROC AUC models
by means of DeLong’s test. Prognostic analyses were
complemented with the net reclassification improvement
(NRI) and the integrated discrimination improvement (IDI)
[28]. Calibration of the model was performed with the Hos-
mer and Lemeshow goodness-of-fit test. For regression
analyses, biomarker values were transformed to a log scale.




Characteristics of all sepsis patients are shown in Table 1.
From a total of 1,103 patients, 786 (71.3 %) survived
until day 30 after ICU admission, whereas 305 (27.7 %)
patients did not; 12 patients were lost to follow up. The
lung was the most common source of infection, followed
by abdominal and urinary tract infections; survivors and
non-survivors had similar sites of infection. As expected,
non-survivors presented with more severe disease, as
reflected by higher APACHE IV and SOFA scores, more
organs failing and more shock. Thirty-day mortality
occurred in 70.2 % of patients in the ICU.
Table 1 Clinical characteristics and outcome of sepsis patients stratified according to survival status 30 days after admission
All patients Survivors Non-survivors P
n = 1103 n = 786 n = 305
Demographics
Age, years, mean (SD) 61.2 (14.7) 59.7 (14.7) 64.9 (13.9) <0.0001
Gender, male, n (%) 671 (60.8) 481 (61.2) 183 (60) 0.73
Race, white, n (%) 972 (88.8) 689 (87.7) 273 (89.5) 0.45
Body mass index, kg/m2, mean (SD) 26 (6.2) 26.2 (6.3) 25.5 (5.8) 0.09
Admission type, medical, n (%) 817 (74.1) 562 (71.5) 247 (81) 0.001
Charlson score, median (IQR) 4 (3–6) 4 (2–6) 5 (3–6) 0.0001
Site of infection
Pulmonary, n (%) 478 (43.3) 337 (37.1) 135 (44.3) 0.69
Abdominal, n (%) 215 (19.5) 150 (19.1) 61 (20) 0.74
Urinary, n (%) 109 (9.9) 84 (10.7) 24 (7.9) 0.69
Other, n (%)a 173 (15.7) 123 (15.6) 49 (16.1) 0.93
Coinfection, n (%) 128 (11.6) 92 (11.7) 36 (11.8) 1
Severity of disease in first 24 hours
APACHE IV score, median (IQR) 80 (63–101) 74 (59–92) 98 (81–122) <0.0001
SOFA score, median (IQR)b 7 (5–9) 7 (4–9) 9 (6–12) <0.0001
Shock, n (%) 373 (33.8) 234 (29.8) 135 (44.3) <0.001
Mechanical ventilation, n (%) 851 (77.2) 590 (75.1) 249 (81.6) <0.05
Renal replacement therapy, n (%) 115 (10.4) 60 (7.6) 53 (17.4) <0.001
Outcome
ICU length of stay, days, median (IQR) 4 (2–10) 5 (2–10) 3 (2–8) <0.01
ICU mortality, n (%) 227 (20.6) 13 (1.7) 214 (70.2) <0.001
12 patients were lost to follow up.aSite of infection: “other” includes cardiovascular infection, mediastinitis and skin infection. bCentral nervous system not
included in score. APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment
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Fractalkine levels are elevated in sepsis patients during
the first 4 days after ICU admission and are associated
with severity of disease
Fractalkine levels, measured in plasma obtained within
24 hours after admission (day 0) and at days 2 and 4, were
consistently elevated in patients with sepsis relative to
healthy controls (Fig. 1a, P <0.0001 for all time points).
On longitudinal analysis there was no effect of time on
plasma fractalkine levels (P = 0.43). In contrast, in sepsis
patients during the first 4 days of the ICU stay there was a
time-dependent decline in plasma IL-6, IL-8 and IL-10
(Additional file 1: Figure S1, P <0.0001 for all analytes),
which are well-known cytokine markers in sepsis [29].
Sustained elevated plasma fractalkine levels after admis-
sion for sepsis were confirmed upon separate analysis of
the two contributing ICUs (data not shown). Fractalkine
concentrations did not differ between sepsis patients with
different sources of infection (Fig. 1b).
Admission fractalkine levels increased with increasing
number of organs failing on admission (Fig. 1c, r = 0.42,
P <0.001). Patients presenting with shock had signifi-
cantly higher fractalkine levels than those without shock
(Fig. 1d). Of the 730 patients not presenting with shock
on admission, 90 (12.3 %) developed shock later during
their stay on the ICU; admission fractalkine levels were
higher in those septic patients who developed shock
Fig. 1 Fractalkine levels are elevated in sepsis and correlate with organ failure. Blood was drawn from patients within 24 hours of admission to the ICU
(day 0) and on days 2 and 4. a Fractalkine levels were elevated in patients compared to healthy volunteers (HV) at all time points, and did
not differ between days 0 and 4. b Fractalkine levels were not influenced by the primary source of infection. c Admission fractalkine levels
in patients with increasing numbers of failing organs at admission. Fractalkine levels were higher in patients with shock on admission (d)
and in patients who developed shock >24 hours after admission (e). Box and whisker diagrams depict the median and lower quartile, upper
quartile, and their respective 1.5 IQR as whiskers (as specified by Tukey). Gray boxes represent sepsis; open box or dotted lines represent
healthy volunteers. ***P <0.001, *P <0.05
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while on the ICU when compared with patients who did
not (Fig. 1e).
Fractalkine levels are higher in non-survivors
To assess the relationship between fractalkine levels and
sepsis mortality, measurements were partitioned in survi-
vors and non-survivors at day 30 after ICU admission.
Fractalkine levels on admission and 2 and 4 days there-
after were significantly higher in non-survivors compared
to survivors (Fig. 2a, P <0.001 for all time points). In a
sub-analysis restricted to patients presenting with shock,
fractalkine remained significantly associated with mortal-
ity (Additional file 2: Figure S2). To further investigate the
association between fractalkine and 30-day mortality,
admission fractalkine levels were partitioned into quartiles
for which log-rank tests were performed. Quartile 3
(50–75 %, 25.5–58.7 pg/ml) and quartile 4 (75–100 %,
58.7–6329.0 pg/ml) of fractalkine levels had statistically
significantly reduced survival (P <0.01 and P <0.001, re-
spectively), compared to quartile 1 (Fig. 2b). Admission
fractalkine levels remained significantly associated with
30-day mortality after adjustment for age, Charlson
comorbidity index, body mass index (BMI), admission
type and APACHE IV scores in a logistic regression
model (odds ratio (OR), 1.37 (95 % CI, 1.19–1.58) for
each log increase in fractalkine, P <0.0001). Similarly,
when fractalkine levels were included in a logistic
regression analysis together with SOFA scores, the
association with 30-day mortality persisted (OR, 1.25,
95 % CI, 1.09–1.44, for each log increase in fractalkine,
P = 0.001). Moreover, plasma levels on days 2 and 4
remained independently associated with 30-day mortal-
ity after adjustment for SOFA scores for those particu-
lar days (OR 1.40, 95 % CI 1.20–1.63, P = 0.001 and OR
1.31, 95 % CI 1.08–1.59, P = 0.006, respectively). The
ROC AUC of fractalkine was 0.65 (95 % CI 0.61–0.69).
The Youden index determined a fractalkine level of
38.2 pg/ml to be the optimal cutoff. At this cutoff,
fractalkine had 54 % sensitivity and 71 % specificity for
predicting mortality at 30 days after ICU admission.
Fractalkine in addition to the APACHE IV score, im-
proved classification of patients who were deceased at
30 days after admission and those who were not; the
NRI was 0.27 (95 % CI 0.12–0.41, P = 0.0003) and the
IDI was 0.02 (95 % CI 0.006–0.02, P = 0.002).
The association between elevated fractalkine con-
centrations and mortality persisted when outcomes
were 7-day, 90-day or 1-year mortality (Additional
file 3: Figure S3). Together these data suggest that
higher fractalkine levels are associated with short-term
mortality, and that this association drives differences in
long-term mortality.
Comparison of fractalkine release with that of soluble
E-selectin
Several studies have identified endothelial cells as a
major source of fractalkine [4, 30, 31]. Considering that
it is difficult to assess whether the endothelium produces
fractalkine during human sepsis in vivo, we compared
the kinetics of fractalkine release into the circulation
relative to that of the established specific endothelial cell
activation marker E-selectin [32, 33] in a controlled
human setting of systemic inflammation induced by
bolus intravenous injection of LPS. Intravenous LPS
induced a rise in fractalkine levels with similar kinetics
to the increase in soluble E-selectin (Fig. 3a, P <0.0001).
The initial increase in soluble E-selectin coincided with
the rise in fractalkine levels, and fractalkine and soluble
Fig. 2 Fractalkine plasma levels are associated with 30-day mortality. Blood was drawn within 24 hours of admission to the ICU (day 0) and days
2 and 4. a Fractalkine levels of survivors and non-survivors at day 30, presented as box and whiskers as specified by Tukey. b Kaplan–Meier plots
of survival time up to 30 days after ICU admission for quartiles (Q1 4.0–13.4 pg/ml, Q2 13.4–25.5 pg/ml, Q3 25.5–58.7 pg/ml, Q4 58.7–6329 pg/ml)
of admission fractalkine levels. Dotted lines in box and whisker plots represent the median level in healthy volunteers (HV). ***P <0.001, **P <0.01
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E-selectin levels measured during the first 5 hours after
LPS injection had strong positive correlation (Fig. 3a;
r = 0.79, P <0.0001). The release of IL-6 occurred
faster and was more transient, and IL-6 levels did not
correlate with fractalkine levels (Additional file 4:
Figure S4). We also measured soluble E-selectin levels
in the patient samples used in Figs. 1 and 2. While
soluble E-selectin levels were clearly elevated in patients
with sepsis when compared with healthy controls (Fig. 3b,
P <0.001), confirming previous reports [34, 35], sol-
uble E-selectin was not associated with increased
mortality at day 30 (Fig. 3c); admission soluble E-
selectin was, in contrast with fractalkine, lower in
non-survivors (P = 0.02). The ROC AUC of soluble
E-selectin for 30-day mortality was 0.55 (95 % CI
0.51–0.59). Fractalkine outperformed soluble E-selectin in
predicting 30-day mortality (P = 0.001).
Elevated plasma fractalkine levels are not specific for
infection
Considerable research has focused on discriminating in-
fectious from non-infectious sources of critical illness.
To determine whether fractalkine levels can provide
diagnostic value we analyzed fractalkine levels in 344
patients consecutively admitted to the ICU with sus-
pected CAP. Of these, 271 patients were classified as
Fig. 3 Soluble E-selectin correlates with fractalkine release after intravenous injection of endotoxin in healthy humans in vivo but is not associated
with increased mortality in sepsis patients. a Fractalkine release after intravenous injection of endotoxin (lipopolysaccharide, 4 ng/kg body weight)
into five healthy subjects compared with E-selectin release. Right panel shows correlation between fractalkine levels and E-selectin measured during
the first 5 hours after endotoxin administration (shaded gray). Data are expressed as mean ± standard error of the mean. b Soluble E-selectin levels
were elevated in patients compared to healthy volunteers (HV) at all time points. c Soluble E-selectin levels of survivors and non-survivors at day 30,
presented as box and whiskers as specified by Tukey. ***P <0.001, **P <0.01, *P <0.05
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having CAP (these were also part of the sepsis cohort
described above), whereas in 73 patients the CAP diag-
nosis was retrospectively refuted (no-CAP controls) [17].
Clinical characteristics of patients with and without CAP
are depicted in Table 2. these patients were largely simi-
lar in demographics, comorbidities, severity of disease
and outcome. Patients with CAP more often had shock
and had longer lengths of stay in the ICU. The ICU
mortality and 30-day mortality did not differ between
groups. Fractalkine levels were similar in patients with
and without CAP on admission and at 2 and 4 days
thereafter (Fig. 4a). Fractalkine levels were higher in pa-
tients with CAP and without CAP who presented with
shock than in those who did not (Fig. 4b); similarly, frac-
talkine levels were higher in patients with and without
CAP who did not survive until day 30, when compared
with those who did (Fig. 4c).
Discussion
Fractalkine is the only member of the CX3C class of
chemokines, and thus far, primarily studied as a potential
mediator of chronic inflammatory conditions. We per-
formed a detailed analysis of plasma fractalkine concentra-
tions during the first 4 days after ICU admission in almost
1,200 acutely ill patients to show that elevated plasma
fractalkine, while not specific for the presence of infection,
is a sustained marker of disease severity and an adverse
outcome in sepsis patients admitted to the ICU.
Fractalkine may not be merely a marker of disease
severity in sepsis. Animal studies have suggested an
important functional role for fractalkine in the patho-
genesis of sepsis. In accordance with our human data,
abdominal sepsis induced by CLP in mice was associated
with elevated plasma fractalkine levels [14, 15]. Elimin-
ation of the biological activity of fractalkine, achieved by
studying mice deficient for its receptor CX3CR1, has
been shown to exaggerate organ damage and increase
lethality [13]. During murine abdominal sepsis, fractalk-
ine mRNA levels are elevated in the heart, lung, kidney,
and liver, indicating that many organs contribute to
elevated plasma concentrations [15].
Although fractalkine can be produced by a variety of
cell types, arterial and capillary endothelial cells have
been identified as a major source during endotoxemia in
rats [31]. In accordance, several studies have reported
the capacity of endothelial cells to produce fractalkine
[4, 30, 31]. As endothelial cells are not easily accessible
for studying production of inflammatory mediators in
patients with sepsis, we used the model of human endo-
toxemia to obtain indirect evidence for the endothelium
as an important source of fractalkine, comparing the
release of fractalkine with that of E-selectin. We
regarded E-selectin a relevant biomarker in this context,
Table 2 Clinical characteristics and outcome of patients with community-acquired pneumonia (CAP) and no-CAP controls
CAP No CAP P
n = 271 n = 73
Demographics
Age, years, mean (SD) 59.7 (16.7) 58.8 (17.2) 0.70
Gender, male, n (%) 155 (57.2) 40 (54.8) 0.79
Race, white, n (%) 236 (87.1) 57 (78.1) 0.04
Body mass index, kg/m2, mean (SD) 24.9 (6.0) 26.4 (9.4) 0.21
Charlson score, median (IQR) 4 (2–6) 3 (2–5) 0.07
Severity of disease in first 24 hours
APACHE IV score, median (IQR) 79 (62–101) 68 (52–99) 0.07
SOFA score, median (IQR)a 7 (4–9) 6 (3–7) 0.01
Shock, n (%) 71 (26.2) 10 (13.7) 0.03
Mechanical ventilation, n (%) 203 (74.9) 57 (78.1) 0.66
Renal replacement therapy, n (%) 19 (7) 4 (5.5) 0.78
Outcome
ICU length of stay, days, median (IQR) 5 (2–11) 2 (1–4) <0.0001
ICU mortality, n (%) 53 (19.6) 9 (12.3) 0.18
30-day mortality, n (%) 73 (26.9) 16 (21.9) 0.37
90-day mortality, n (%) 92 (33.9) 19 (26) 0.16
1-year mortality, n (%) 121 (44.6) 30 (41.1) 0.50
All patients were treated for suspected CAP upon ICU admission and classified in retrospect as having or not having CAP, as described in “Methods”. aCentral
nervous system not included in score. APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment
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considering that it is endothelial-cell-specific [36], and
that increased endothelial cell expression of fractalkine
and E-selectin by inflammatory stimuli is mediated
by similar mechanisms involving activation of NF-κB
[30, 37]; moreover, the release of both fractalkine and E-
selectin from endothelial cells is regulated by members of
the family of disintegrins and metalloproteinases [38, 39].
We indeed found remarkably similar kinetics for the
appearance of fractalkine and E-selectin in the circula-
tion after intravenous injection of LPS, and fractalkine
levels were positively and significantly correlated with
E-selectin levels. Together these data suggest endothelial
cells are a major source of fractalkine in sepsis. Blood
leukocytes are an unlikely source of fractalkine in sepsis,
Fig. 4 Fractalkine levels in patients with community-acquired pneumonia (CAP) and critically ill patients with no CAP. Blood was drawn from patients
within 24 hours of admission to the ICU (day 0) and at days 2 and 4. a Fractalkine plasma levels in patients with suspected CAP upon ICU admission
and classified in retrospect as having CAP or no CAP. Differences between groups were not significant. b Fractalkine levels were higher in patients with
shock on admission (b) and in non-survivors (at day 30) (c) in both CAP and no-CAP patients. Box and whisker diagrams depict the median and lower
quartile, upper quartile, and their respective 1.5 IQR as whiskers (as specified by Tukey). Dotted lines represent the median level in healthy volunteers
(HV). ***P <0.001, *P <0.05
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as whole blood leukocytes did not release fractalkine upon
stimulation with Toll-like receptor ligands relevant for
common sepsis pathogens (data not shown). In accord-
ance, fractalkine mRNA levels were undetectable in
blood leukocytes from a subgroup of 440 sepsis pa-
tients in whom the genome-wide transcriptome was
assessed (data not shown).
A substantial number of biomarkers have been pro-
posed for the diagnostic stratification of infectious and
non-infectious ICU patients [29], most notably procalcito-
nin [40]. To the best of our knowledge, published data on
fractalkine levels in an ICU setting is limited to a single
study reporting fractalkine concentrations in 43 patients
with septic shock [16]. Considering that circulating frac-
talkine concentrations are elevated in a variety of chronic
non-infectious inflammatory conditions [41–45], we ar-
gued that elevated fractalkine levels are likely not specific
for the presence of infection upon ICU admission. To
address this, we measured fractalkine levels in critically ill
patients suspected of having CAP upon ICU admission,
who in retrospect were classified as having an infection
likelihood of ‘definite’ or ‘probable’ (CAP patients), or
‘none’ (no-CAP patients). The likelihood of the CAP diag-
nosis was classified by dedicated research physicians by
post hoc review of all available clinical, radiological, and
microbiological evidence, and using strict diagnostic
criteria [17]; the interobserver agreement for the diagnosis
and likelihood of CAP was excellent [17]. By using this
additional ICU cohort we clearly show that fractalkine
cannot be considered a marker for infection in critically ill
patients. Also elevated fractalkine levels were associated
with increased disease severity and an adverse outcome in
patients without CAP.
How could fractalkine levels be of use at the bedside?
Many different biomarkers for diagnosis of infection and
ICU prognosis have been described in the literature, and
none of these are currently used in clinical practice [29].
The challenge for future clinical implementation is to
define combinations of biomarkers concurrently mea-
sured at the bedside that together with clinical readouts
provide useful information for detection of infection
and risk stratification [46]. The current study suggests
that plasma fractalkine levels could be part of a test
aiding in risk stratification during the first days after
ICU admission.
Conclusions
This large observational study suggests that plasma frac-
talkine, while not specific for infection, is a sustained
biomarker of disease severity and outcome in sepsis pa-
tients admitted to the ICU, irrespective of the primary
source of infection and is likely derived from the acti-
vated vascular endothelium.
Key messages
 Plasma fractalkine is an endothelial-cell-derived
biomarker
 Fractalkine levels are elevated in sepsis patients
during the first 4 days after ICU admission
 Fractalkine levels are strongly associated with
severity of disease and adverse outcome
 Elevated plasma fractalkine levels are not specific
for infection in the critically ill
Additional files
Additional file 1: Figure S1. Elevated IL-6, IL-8 and IL-10 levels in sepsis
patients. Blood was drawn from patients within 24 hours of admission to
the ICU (day 0) and at days 2 and 4. IL-6 (a), IL-8 (b) and IL-10 (c) levels were
measured in plasma. Box and whisker diagrams depict median and
lower quartile, upper quartile, and their respective 1.5 IQR as whiskers
(as specified by Tukey). Gray boxes, sepsis patients (n = 1,103), open
boxes, healthy volunteers (HV, n = 27). ***P <0.001 for sepsis patients
compared to HV and for decline over time. (DOC 151 kb)
Additional file 2: Figure S2. Fractalkine plasma levels are associated
with mortality in patients with shock within 24 hours of admission.
Patient blood was drawn within 24 hours of admission to the ICU (day 0)
and at days 2 and 4. Fractalkine levels of 30-day survivors and non-survivors
in a subgroup of patients admitted with shock. Box and whisker diagrams
depict median and lower quartile, upper quartile, and their respective 1.5
IQR as whiskers (as specified by Tukey). Dotted lines in boxes, median level in
healthy volunteers (HV). **P <0.01, *P <0.05. (DOC 83 kb)
Additional file 3: Figure S3. Elevated fractalkine plasma levels are
associated with short- and long-term mortality. Patient blood was drawn
within 24 hours of admission to the ICU (day 0) and at days 2 and 4.
Fractalkine levels are shown for survivors and non-survivors at day 7 (a),
day 90 (b) and one year (c) after ICU admission. Box and whisker diagrams
depict median and lower quartile, upper quartile, and their respective 1.5
IQR as whiskers (as specified by Tukey). Dotted lines in boxes, median level in
healthy volunteers. ***P <0.001. (DOC 81 kb)
Additional file 4: Figure S4. Fractalkine compared to IL-6 release after
intravenous injection of endotoxin to healthy humans in vivo. Fractalkine
release after intravenous injection of endotoxin (lipopolysaccharide, 4 ng/
kg body weight) into five healthy subjects compared with IL-6 release.
Right panel, correlation between fractalkine levels and IL-6 measured during
the first 5 hours after endotoxin administration (gray). Data are expressed as
mean ± standard error of the mean. (DOC 135 kb)
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